Alexion Pharma (ALXN) reported earnings on Mon 4 Feb 2019 (b/o)

** charts after earnings **

 

Alexion Pharma beats by $0.30, beats on revs; guides FY19 EPS above consensus, revs below consensus

• Reports Q4 (Dec) earnings of $2.14 per share, excluding non-recurring items, $0.30 better than the S&P Capital IQ Consensus of $1.84; revenues rose 24.1% year/year to $1.13 bln vs the $1.06 bln S&P Capital IQ Consensus.
• SOLIRIS net product sales were $976.7 million, compared to $791.9 million in the fourth quarter of 2017, representing a 23 percent increase. SOLIRIS volume increased 28 percent year-over-year.
• Co issues guidance for FY19, sees EPS of $9.10-9.30 vs. $8.80 S&P Capital IQ Consensus; sees FY19 revs of $4.625-4.7 bln vs. $4.75 bln S&P Capital IQ Consensus.